Study details
Enrolling now
Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Brigham and Women's Hospital
NCT IDNCT04701645ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
20
Study length
about 3.7 years
Ages
18+
Sex
Female only
Locations
2 sites in MA
About this study
This trial is testing a new way to measure how well cancer responds to treatment using an implantable microdevice. The goal of this pilot trial is to determine if the device can accurately track local tumor response in women with ovarian, fallopian tube, or primary peritoneal cancers.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Microdevice
PhasePhase 1
Primary goalNumber of participants with adverse events as defined in the CTCAE v5.0
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low10%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Number of participants with adverse events as defined in the CTCAE v5.0
Body systems
Oncology